Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Company Overview - Leap Therapeutics, Inc. is a biotechnology company focused on developing targeted and immuno-oncology therapeutics [3] - The company's most advanced clinical candidate is DKN-01, a humanized monoclonal antibody targeting the Dickkopf1 (DKK1) protein, which is being developed for esophagogastric, colorectal, and gynecological cancers [3] - Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, currently in preclinical development [3] Upcoming Events - Douglas E. Onsi, President and CEO of Leap Therapeutics, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference [1] - The event is scheduled for December 4, 2024, at 4:00 p.m. Eastern Time, and will be accessible via a live webcast on the company's Investors page [2]